Funds advised by SK Capital Partners (SK Capital), a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, has acquire a majority shareholding in SEQENS, a pharmaceutical solutions and specialty ingredients companies.
SK Capital is investing alongside several other investors including Bpifrance, the French national investment bank, Nov Santé, Mérieux Equity Partners, Ardian, Eximium and the Company’s management team.
Concurrent with the acquisition, SEQENS entered a combination with Wavelength Pharmaceuticals, an existing SK Capital portfolio company which is also a global manufacturer and developer of active pharmaceutical ingredients. Additionally, prior to the closing, SEQENS divested certain non-core mineral specialties assets, including the sodium bicarbonate, soda ash and sodium silicate production facilities in Laneuveville-devant-Nancy (France), Nogent L’Artaud (France) and Jurong Island (Singapore).
